Роль нарушений моторики в патогенезе функциональных расстройств желудочнокишечного тракта и современные возможности их лечения (Резолюция Экспертного совета и обзор литературы)

Aim . To present the materials of an Expert Council, which was held on September 23, 2019 in Istanbul (Turkey) under the auspices of a World Gastroenterology Organisation congress and the support of the Abbott company. General provisions . During the work of the Expert Council, the role of motility disorders of the stomach and duodenum, intestines, gall bladder and the sphincter of Oddi in the development of functional diseases of the digestive system, such as functional dyspepsia (FD), irritable bowel syndrome (IBS), biliary dyskinesia (BD) was discussed, and the effectiveness of antispasmodics and prokinetics in their treatment was shown. At the same time, the advantages of the mebeverin antispasmodic drug, as well as the high efficiency and safety of the itopride hydrochloride prokinetic drug were noted. It is emphasized that, at the stage of a diagnostic search in the absence of “alarm symptoms” in patients with suspected FD, IBS, and BD, these drugs can be prescribed empirically. Conclusions. When selecting pharmacotherapy for patients with motor impairment, it is extremely important to consider the nature of these disorders. The use of modern medical preparations, which are characterized by a high level of safety and the targeted action towards a specific motility disorder, allows optimal therapy results to be achieved with minimal risks for the patient.

[1]  C. Shin,et al.  Helicobacter pylori Eradication Therapy for Functional Dyspepsia: A Meta-Analysis by Region and H. pylori Prevalence , 2019, Journal of clinical medicine.

[2]  Т. Л. Лапина,et al.  Клинические рекомендации Российской гастроэнтерологической ассоциации по диагностике и лечению дискинезии желчевыводящих путей , 2018 .

[3]  J. Tack,et al.  383 - The Therapeutic Outcome of Itopride in Functional Dyspepsia Postprandial Distress Syndrome: A Double-Blind Randomized, Multicenter, Placebo-Controlled Study , 2018 .

[4]  Т. Л. Лапина,et al.  Клинические рекомендации Российской гастроэнтерологической ассоциации по диагностике и лечению функциональной диспепсии , 2017 .

[5]  John J Kim,et al.  Helicobacter pylori eradication therapy for functional dyspepsia: Systematic review and meta-analysis. , 2016, World journal of gastroenterology.

[6]  Jan Tack,et al.  Gastroduodenal Disorders. , 2016, Gastroenterology.

[7]  Xuan Huang,et al.  Itopride therapy for functional dyspepsia: a meta-analysis. , 2012, World journal of gastroenterology.

[8]  G. Buzás Quality of life in patients with functional dyspepsia: Short- and long-term effect of Helicobacter pylori eradication with pantoprazole, amoxicillin, and clarithromycin or cisapride therapy: A prospective, parallel-group study. , 2006, Current therapeutic research, clinical and experimental.

[9]  N. Talley,et al.  A placebo-controlled trial of itopride in functional dyspepsia. , 2006, The New England journal of medicine.